STOCK TITAN

Labcorp (NYSE: LH) EVP nets 4,106 shares after RSU vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Labcorp Holdings Inc. executive Akinbolade Oyegunwa exercised restricted stock units and had shares withheld for taxes. On February 11, 2026, 230 restricted stock units converted into 230 shares of common stock. Of these, 68 shares were withheld to cover tax obligations at $289.89 per share.

Following these transactions, Oyegunwa directly held 4,106.253 shares of common stock and 2,190 restricted stock units. The vested units came from a grant scheduled to vest in three equal annual installments beginning on February 11, 2026.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Oyegunwa Akinbolade

(Last) (First) (Middle)
531 SOUTH SPRING STREET

(Street)
BURLINGTON NC 27215

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, CIO & CTO
3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/11/2026 M 230 A (1) 4,174.253 D
Common Stock 02/11/2026 F(2) 68 D $289.89 4,106.253 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 02/11/2026 M 230 (3) (3) Common Stock 230 $0 2,190(4) D
Explanation of Responses:
1. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
2. Stock withholding to satisfy tax withholding obligations.
3. The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2026.
4. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
/s/ Kathryn W. Kyle, Attorney-in-Fact for Akinbolade Oyegunwa 02/13/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Labcorp (LH) report for Akinbolade Oyegunwa?

Labcorp reported that EVP, CIO & CTO Akinbolade Oyegunwa exercised 230 restricted stock units into common shares. As part of the same event, 68 shares were withheld to satisfy tax obligations, leaving him with 4,106.253 directly held common shares and 2,190 restricted stock units.

How many Labcorp (LH) shares does Akinbolade Oyegunwa hold after this Form 4?

After the reported transactions, Akinbolade Oyegunwa directly holds 4,106.253 Labcorp common shares. In addition, he beneficially owns 2,190 restricted stock units, each representing the contingent right to receive one Labcorp common share upon vesting under the company’s equity award terms.

What do the restricted stock unit exercises mean for Labcorp (LH) insider ownership?

The filing shows 230 restricted stock units converted into 230 Labcorp common shares for Oyegunwa. This increases his directly held stock while reducing outstanding restricted units, and reflects ongoing vesting from a prior equity grant with three equal annual installments starting February 11, 2026.

Why were 68 Labcorp (LH) shares disposed of in this Form 4?

The 68-share disposition was a tax-withholding transaction at $289.89 per share. Shares were withheld to satisfy Oyegunwa’s tax obligations related to the restricted stock unit vesting, rather than a discretionary open-market sale, which is common in equity compensation events.

How is the Labcorp (LH) restricted stock unit grant structured for this insider?

The restricted stock units that vested for Oyegunwa come from a grant vesting in three equal annual installments. The schedule begins on February 11, 2026, meaning additional units may vest on the same date in subsequent years if grant conditions continue to be met.

What is the relationship of Akinbolade Oyegunwa to Labcorp (LH)?

Akinbolade Oyegunwa is an officer of Labcorp, serving as Executive Vice President, Chief Information Officer and Chief Technology Officer. His Form 4 filing reflects equity compensation activity tied to this leadership role, including restricted stock unit vesting and related tax-withholding share dispositions.
Labcorp Holdings Inc

NYSE:LH

LH Rankings

LH Latest News

LH Latest SEC Filings

LH Stock Data

23.32B
81.71M
Diagnostics & Research
Services-medical Laboratories
Link
United States
BURLINGTON